{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "exchangeTimezoneName": "Australia/Sydney", "exchangeTimezoneShortName": "AEST", "currency": "AUD", "market": "au_market", "esgPopulated": false, "gmtOffSetMilliseconds": 36000000, "exchange": "ASX", "longName": "Telix Pharmaceuticals Limited", "shortName": "TELIXPHARM FPO", "regularMarketPrice": 11.32, "regularMarketChangePercent": 0.17698675, "messageBoardId": "finmb_537247297", "marketState": "POSTPOST", "fiftyTwoWeekHighChangePercent": -0.013937269, "fiftyTwoWeekLow": 3.59, "fiftyTwoWeekHigh": 11.48, "earningsTimestamp": 1681729140, "earningsTimestampStart": 1681729140, "earningsTimestampEnd": 1681729140, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "fiftyTwoWeekLowChange": 7.7299995, "fiftyTwoWeekLowChangePercent": 2.1532032, "fiftyTwoWeekRange": "3.59 - 11.48", "fiftyTwoWeekHighChange": -0.15999985, "epsTrailingTwelveMonths": -0.35, "epsForward": 0.26, "epsCurrentYear": 0.19, "priceEpsCurrentYear": 59.578945, "sharesOutstanding": 318358016, "bookValue": 0.253, "fiftyDayAverage": 8.2816, "fiftyDayAverageChange": 3.0383997, "fiftyDayAverageChangePercent": 0.3668856, "twoHundredDayAverage": 7.01935, "twoHundredDayAverageChange": 4.3006496, "twoHundredDayAverageChangePercent": 0.6126849, "marketCap": 3603812608, "forwardPE": 43.538464, "priceToBook": 44.743084, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1510700400000, "priceHint": 2, "regularMarketChange": 0.019999504, "regularMarketTime": 1683871827, "regularMarketDayHigh": 11.48, "regularMarketDayRange": "11.17 - 11.48", "regularMarketDayLow": 11.17, "regularMarketVolume": 1362212, "regularMarketPreviousClose": 11.3, "bid": 11.31, "ask": 11.32, "bidSize": 0, "askSize": 0, "fullExchangeName": "ASX", "financialCurrency": "AUD", "regularMarketOpen": 11.3, "averageDailyVolume3Month": 1257881, "averageDailyVolume10Day": 1466304, "symbol": "TLX.AX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "55 Flemington Road", "address2": "Suite 401", "city": "North Melbourne", "state": "VIC", "zip": "3051", "country": "Australia", "phone": "61 3 3093 3897", "website": "https://telixpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.", "fullTimeEmployees": 234, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA", "age": 46, "title": "Co-Founder, Group MD, CEO & Exec. Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 599226, "fmt": "599.23k", "longFmt": "599,226"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Darren  Smith B.Bus., FCPA, M.B.A.", "age": 57, "title": "Group Chief Financial Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 245859, "fmt": "245.86k", "longFmt": "245,859"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Andreas  Kluge M.D., Ph.D.", "title": "Chief Medical Advisor & Director (Leave of Absence)", "fiscalYear": 2022, "totalPay": {"raw": 86000, "fmt": "86k", "longFmt": "86,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Colin  Hayward FFPM, MBBS", "title": "Group Chief Medical Officer", "fiscalYear": 2022, "totalPay": {"raw": 683899, "fmt": "683.9k", "longFmt": "683,899"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Richard  Valeix M.B.A.", "title": "Group Chief Commercial Officer", "fiscalYear": 2022, "totalPay": {"raw": 558483, "fmt": "558.48k", "longFmt": "558,483"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael  Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)", "title": "Chief Scientist", "fiscalYear": 2017, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Kyahn  Williamson B.A.", "title": "Sr. VP of Corp. Communications & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Melanie  Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C.", "title": "Sr. VP of Global Governance, Risk & Compliance", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lena  Moran-Adams L.L.B.", "title": "Gen. Counsel", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christian  Davis", "title": "VP Sales and Marketing, EMEA", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 2, "compensationRisk": 5, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}